These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 2989445)

  • 1. Treatment of nasopharyngeal carcinoma with human leukocyte interferon.
    Connors JM; Andiman WA; Howarth CB; Liu E; Merigan TC; Savage ME; Jacobs C
    J Clin Oncol; 1985 Jun; 3(6):813-7. PubMed ID: 2989445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Value of anti-Epstein-Barr antibody detection in the diagnosis and management of undifferentiated carcinoma of the nasopharynx].
    Mazeron MC
    Bull Cancer Radiother; 1996; 83(1):3-7. PubMed ID: 8679277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant interferon-gamma in the treatment of recurrent nasopharyngeal carcinoma.
    Dimery IW; Jacobs C; Tseng A; Saks S; Pearson G; Hong WK; Gutterman JU
    J Biol Response Mod; 1989 Jun; 8(3):221-6. PubMed ID: 2545832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC).
    Liu MT; Yeh CY
    Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IgG and IgA antibodies to Epstein-Barr virus in nasopharyngeal carcinoma patients.
    Gong SH; Lynn TC; Yang CS
    Zhonghua Min Guo Wei Sheng Wu Xue Za Zhi; 1978 Mar; 11(1):8-15. PubMed ID: 211015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serologic diagnosis of nasopharyngeal carcinoma. A double-blind study of four EB virus antibodies with evaluation by sequential discrimination.
    Cai WM; Li YW; Wu B; Liu YY; Hu YH; Gu XZ; Liu HY; Wang GD
    Int J Radiat Oncol Biol Phys; 1983 Dec; 9(12):1763-8. PubMed ID: 6319338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus-associated antibodies and serum biochemistry in nasopharyngeal carcinoma.
    Lynn TC; Hsieh RP; Chuang CY; Huang SC; Hsieh T; Tu SM
    Laryngoscope; 1984 Nov; 94(11 Pt 1):1485-8. PubMed ID: 6092804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, tonsillar carcinoma and control groups.
    Oberender H; Nowak R; Donner A; Kunkel M; Gärtner L; Scholtz HJ
    Acta Virol; 1983 May; 27(3):277-81. PubMed ID: 6138990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
    Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
    J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC).
    Levine PH; Pearson GR; Armstrong M; Bengali Z; Berenberg J; Easton J; Goepfert H; Henle G; Henle W; Heffner D; Huang A; Hyams VJ; Lanier A; Neel HB; Pilch B; Pointek N; Taylor W; Terebelo H; Weiland L
    Cancer Detect Prev; 1981; 4(1-4):307-12. PubMed ID: 6299561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr virus-related serology in nasopharyngeal carcinoma and controls.
    Henle W; Henle G; Ho JH
    IARC Sci Publ (1971); 1978; (20):427-37. PubMed ID: 215525
    [No Abstract]   [Full Text] [Related]  

  • 13. Serological and immunohistological assessment of Epstein-Barr virus infection in Sicilian patients with suspected nasopharyngeal carcinoma.
    Ammatuna P; de Thè G; Speciale R; Sammartano F; Arista S; Zerillo G
    Microbiologica; 1988 Apr; 11(2):89-94. PubMed ID: 2841559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and immunological considerations in Epstein-Barr virus-associated diseases.
    Andersson J
    Scand J Infect Dis Suppl; 1996; 100():72-82. PubMed ID: 8860357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma.
    Shao JY; Huang XM; Yu XJ; Huang LX; Wu QL; Xia JC; Wang HY; Feng QS; Ren ZF; Ernberg I; Hu LF; Zeng YX
    Anticancer Res; 2001; 21(4B):3021-9. PubMed ID: 11712805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of IgG and IgA type antibodies to capsid and early antigens of the Epstein-Barr virus in the diagnosis of nasopharyngeal carcinoma].
    Mendoza J; Rojas A; de la Rosa M; Amador JM; Expósito J; Esquivias J
    Med Clin (Barc); 1991 Nov; 97(16):609-11. PubMed ID: 1662737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic implication of pretreatment titer of serum immunoglobulin A against Epstein-Barr virus capsid antigen in nasopharyngeal carcinoma patients in Sihui, Guangdong.
    Ling W; Cao SM; Huang QH; Li YH; Deng MQ
    Ai Zheng; 2009 Jan; 28(1):57-9. PubMed ID: 19448418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein-Barr virus (EBV) serology for predicting distant metastases in a white juvenile patient with nasopharyngeal carcinoma and no clinical response to EBV lytic induction therapy.
    Stevens SJ; Zwaan CM; Verkuijlen SA; Middeldorp JM
    Head Neck; 2006 Nov; 28(11):1040-5. PubMed ID: 16933315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [IgG- and IgA-antibodies to the Epstein-Barr virus in the sera of patients with nasopharyngeal carcinoma in Cuba].
    Gurtsevich VE; Ruíz García R; Cuevas J; Le Riverand Morales E; Ascue M
    Vopr Virusol; 1979; (4):392-9. PubMed ID: 225887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of IgA specific antibodies to Epstein-Barr virus capsid and early antigens in nasopharyngeal carcinoma.
    Puthavathana P; Kositanont U; Chongkolwatana C; Metheetrairut C; Chantarakul N; Nuntarakchaikul S; Wasi C
    Asian Pac J Allergy Immunol; 1993 Jun; 11(1):39-43. PubMed ID: 8216557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.